Study of the Potential Role of Serum Neutrophil Gelatinase-Associated Lipocalin (NGAL) Levels in the Diagnosis and Prognosis of Breast Cancer in Egyptian Females "A Case-Control Study"

Main Article Content

F. Z. Mohammed
Lamis Gamal
Mohamed Farouk Mosa
I. M. El- deen

Abstract

Background: Breast cancer (BC) is the most common cause of malignancy in females all over the world. Continuous scientific research for the discovery of new markers helping is a cornerstone for early disease detection and proper management.

Aim of the Study: This study aimed to evaluate the role of Neutrophil gelatinase-associated lipocalin (NGAL) as prognostic markers for breast cancer in an Egyptian female population.

Patients and Methods: 120 BC patients and 30 healthy controls were the subjects of the study; serum NGAL levels were investigated and correlated with the clinicopathologic characteristics of the BC patients.

Results: Our study showed that NGAL was significantly different between healthy controls and BC patients, and  it revealed a gradual increase with disease severity.

Conclusion: Our findings suggested that NGAL could be diagnostic marker for early case detection, and was shown to be associated with breast cancer prognosis, supporting its role as prognostic biomarker.

Keywords:
Breast cancer, NGAL, diagnosis, prognosis

Article Details

How to Cite
Mohammed, F. Z., Gamal, L., Mosa, M. F., & deen, I. M. E.-. (2020). Study of the Potential Role of Serum Neutrophil Gelatinase-Associated Lipocalin (NGAL) Levels in the Diagnosis and Prognosis of Breast Cancer in Egyptian Females "A Case-Control Study". Asian Journal of Research in Biochemistry, 7(1), 1-8. https://doi.org/10.9734/ajrb/2020/v7i130128
Section
Original Research Article

References

Banegas MP, Bird Y, Moraros J, King S, Prapsiri S, Thompson B. Breast cancer knowledge, attitudes, and early detection practices in United States-Mexico border Latinas. Journal of Women's Health. 2012; 21(1):101-107.

Nicolini A, Carpi A, Ferrari P, Rossi G. Immunotherapy prolongs the serum CEA-TPA-CA15.3 lead time at the metastatic progression in endocrine-dependent breast cancer patients: A retrospective longitudinal study. Cancer Lett. 2008;263: 122-129.

Flower DR. The lipocalin protein family: Structure and function. Biochem J. 1996; 318(1):1-14.

Wang YU, Zeng T. Neutrophil gelatinase associated lipocalin protein as a biomarker in the diagnosis of breast cancer: A meta analysis. Biomedical Reports. 2013;1:479-483.

Garner J. In the case of breast cancer, how can these be combined to give prognostic information? Questions for the MRCS vivas. 2004; London: Arnold; 231.

Abdel-Aziz T, Azab N, Emara N, Odah M, El-deen IM. Study of BRCA2 gene mutations in egyptian females with breast cancer. International Journal of Innovative Research in Science. 2015;4(2):283-288.

Fryczkowski M, Bułdak J, Hejmo T, Kukla M, Żwirska-Korczala K. Circulating levels of NGAL, leptin, VEGF, and HGF and their clinical relevance with PSA marker in prostate cancer. Disease Markers. 2018; 3852401:9-21.

Kim Y, Seok JY, Hyun KY, Lee GH, Choi SC. Correlation of glasgowpronostic score or procalcitonin to clinical variables in patients with pretreatment lung cancer. Biomedical Science Letter. 2016;22:9-17.

Kurozumi S, Alsaeed S, Orah N. Clinicopathological significance of lipocalin 2 nuclear expression in invasive breast cancer. Breast Cancer Res Treat. 2020; 179:557-564.

Soni SS, Ronco C, Katz N, Cruz DN. Early diagnosis of acute kidney injury: The promise of novel biomarkers. Blood Purif. 2009;28(3):165-174.

Devarajan P. Review: Neutrophil gelatinase-associated lipocalin: A troponin-like biomarker for human acute kidney injury. Nephrology (Carlton). 2010;15(4): 419-428.

Roli L, Pecoraro V, Trenti T. Can NGAL be employed as prognostic and diagnostic biomarker in human cancers? A systematic review of current evidence. The International Journal of Biological Markers. 2017;32(1):53–61.

Wu Y, Sarkissyan M, Vadgama JV. Epithelial-mesenchymal transition and breast cancer. J Clin Med. 2016;5:E13.

Masuda H, Baggerly KA, Wang Y. Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes. Clin Cancer Res. 2013;19:5533–5540.

Wang YP, Yu GR, Lee MJ. Lipocalin-2 negatively modulates the epithelial-to-mesenchymal transition in hepatocellular carcinoma through the epidermal growth factor (TGF-beta1)/ Lcn2/Twist1 pathway. Hepatology. 2013;58:1349-1361.

Leung L, Radulovich N, Zhu CQ. Lipocalin2 promotes invasion, tumorigenicity and gemcitabine resistance in pancreatic ductal adenocarcinoma. PLoS One. 2012;7(10):e46677.

Feng M, Feng J, Chen W. Lipocalin2 suppresses metastasis of colorectal cancer by attenuating NF-κB-dependent activation of snail and epithelial mesenchymal transition. Mol Cancer. 2016;15:77.

Leng X, Ding T, Lin H. Inhibition of lipocalin 2 impairs breast tumorigenesis and metastasis. Cancer Res. 2009;69:8579-8584.

Wang YU, Zeng T. Neutrophil gelatinase associated lipocalin protein as a biomarker in the diagnosis of breast cancer: A meta analysis. Biomedical Reports. 2013;1:479-483.

Provatopoulou X, Gounaris A, Kalogera E, Zagouri F, Flessas I, Goussetis E, Nonni A, Papassotiriou I,Zografos G. Circulating levels of matrix metalloproteinase-9 (MMP-9), neutrophil gelatinase-associated lipocalin (NGAL) and their complex MMP-9/NGAL in breast cancer disease. BMC Cancer. 2009;9(390).

Yang J, Bielenberg DR, Rodig SJ, Doiron R, Clifton MC, Kung AL, Strong RK, Zurakowski D, Moases MA.Lipocalin 2 promotes breast cancer progression. PNAS. 2009;106:3913-8.

Candido S, Maestro R, Polesel J, Catania A, Maira F, Signorelli S, McCubrey J, Libra M. Roles of neutrophil gelatinase-associated lipocalin (NGAL) in human cancer. Oncotarget. 2014;5(6).

Bauer M, Eickhoff JC, Gould MN, Mundhenke C, Maass N, Friedl A. Neutrophil gelatinase-associated lipocalin (NGAL) is a predictor of poor prognosis in human primary breast cancer. Breast Cancer Res Treat. 2008;108(3):389-397.

Li SH, Hawthorne VS, Neal CL, Sanghera S, Xu J, Yang J, Guo H, Steeg PS, Yu D. Upregulation of neutrophil gelatinase-associated lipocalin by ErbB2 through nuclear factor-kappaB activation. Cancer Res. 2009;69:9163-8.